×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
DNLI – denali therapeutics inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
DNLI
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/16
07:05 am
dnli
Denali Therapeutics Inc. (NASDAQ: DNLI) was upgraded by analysts at Stifel Nicolaus from a "hold" rating to a "buy" rating. They now have a $37.00 price target on the stock.
Low
Report
Denali Therapeutics Inc. (NASDAQ: DNLI) was upgraded by analysts at Stifel Nicolaus from a "hold" rating to a "buy" rating. They now have a $37.00 price target on the stock.
12/6
01:00 pm
dnli
Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report? [Yahoo! Finance]
Low
Report
Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report? [Yahoo! Finance]
12/6
10:57 am
dnli
Denali Starts Dosing in Phase II Parkinson's Disease Study [Yahoo! Finance]
Low
Report
Denali Starts Dosing in Phase II Parkinson's Disease Study [Yahoo! Finance]
12/5
08:10 am
dnli
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson's Disease [Yahoo! Finance]
Low
Report
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson's Disease [Yahoo! Finance]
12/5
08:00 am
dnli
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease
Low
Report
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease
11/16
08:59 am
dnli
Denali Has A Neurodegenerative Edge Despite Market Skepticism [Seeking Alpha]
Medium
Report
Denali Has A Neurodegenerative Edge Despite Market Skepticism [Seeking Alpha]
11/15
08:48 am
dnli
We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely [Yahoo! Finance]
High
Report
We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely [Yahoo! Finance]
11/8
11:57 am
dnli
Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging [Yahoo! Finance]
Medium
Report
Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging [Yahoo! Finance]
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/27
04:45 pm
dnli
Form 4 Denali Therapeutics Inc. For: Nov 25 Filed by: Ho Carole
Low
Report
Form 4 Denali Therapeutics Inc. For: Nov 25 Filed by: Ho Carole
11/26
05:20 pm
dnli
Form 4 Denali Therapeutics Inc. For: Nov 22 Filed by: Schuth Alexander O.
Low
Report
Form 4 Denali Therapeutics Inc. For: Nov 22 Filed by: Schuth Alexander O.
11/18
04:03 pm
dnli
Form 8-K Denali Therapeutics Inc. For: Nov 12
Low
Report
Form 8-K Denali Therapeutics Inc. For: Nov 12
11/13
04:19 pm
dnli
Form 4 Denali Therapeutics Inc. For: Nov 11 Filed by: Schenkein David P
Medium
Report
Form 4 Denali Therapeutics Inc. For: Nov 11 Filed by: Schenkein David P
11/12
04:45 pm
dnli
Form 4 Denali Therapeutics Inc. For: Nov 07 Filed by: Schuth Alexander O.
Low
Report
Form 4 Denali Therapeutics Inc. For: Nov 07 Filed by: Schuth Alexander O.
11/12
04:43 pm
dnli
Form 4 Denali Therapeutics Inc. For: Nov 07 Filed by: SATO VICKI L
Low
Report
Form 4 Denali Therapeutics Inc. For: Nov 07 Filed by: SATO VICKI L
11/12
12:53 pm
dnli
Form SC 13G Denali Therapeutics Inc. Filed by: Capital Research Global Investors
Low
Report
Form SC 13G Denali Therapeutics Inc. Filed by: Capital Research Global Investors
11/12
09:56 am
dnli
Form SC 13G/A Denali Therapeutics Inc. Filed by: FMR LLC
Medium
Report
Form SC 13G/A Denali Therapeutics Inc. Filed by: FMR LLC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/14
Denali Therapeutics Announces Broad Pipeline Progress Including Positive Results From Its LRRK2 Program for Parkinson’s Disease
29.4%
1/26 Denali Therapeutics Inc (NASDAQ: DNLI) was upgraded by analysts at Goldman Sachs Group Inc from a "neutral" rating to a "buy" rating. 13.7%
4/1 Form 4/A Denali Therapeutics Inc. For: Feb 08 Filed by: Watts Ryan J. 8.9%
3/13 Denali Therapeutics Inc (NASDAQ: DNLI) was upgraded by analysts at Evercore ISI to an "outperform" rating. 7.9%
7/2 Denali Therapeutics Inc (NASDAQ: DNLI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $23.00 price target on the stock. 6.2%
10/21 Denali Therapeutics Inc (NASDAQ: DNLI) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 5.7%
1/30 Goldman Sachs: These 2 Stocks Are Poised to Surge by at Least 35% [Yahoo! Finance News] 5.3%
12/3 30 Under 30 2020: Meet The Sports World’s Brightest Young Stars [Forbes] 4.6%
6/15 Denali Therapeutics Inc (NASDAQ: DNLI) was downgraded by analysts at TheStreet from a "c-" rating to a "d" rating. 4.5%
11/26 Form 4 Denali Therapeutics Inc. For: Nov 22 Filed by: Schuth Alexander O. 4.5%
1/26 Denali Therapeutics Inc (NASDAQ: DNLI) was upgraded by analysts at Goldman Sachs Group Inc from a "neutral" rating to a "buy" rating. 13.7%
4/1 Form 4/A Denali Therapeutics Inc. For: Feb 08 Filed by: Watts Ryan J. 8.9%
3/13 Denali Therapeutics Inc (NASDAQ: DNLI) was upgraded by analysts at Evercore ISI to an "outperform" rating. 7.9%
7/2 Denali Therapeutics Inc (NASDAQ: DNLI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $23.00 price target on the stock. 6.2%
10/21 Denali Therapeutics Inc (NASDAQ: DNLI) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 5.7%
1/30 Goldman Sachs: These 2 Stocks Are Poised to Surge by at Least 35% [Yahoo! Finance News] 5.3%
12/3 30 Under 30 2020: Meet The Sports World’s Brightest Young Stars [Forbes] 4.6%
6/15 Denali Therapeutics Inc (NASDAQ: DNLI) was downgraded by analysts at TheStreet from a "c-" rating to a "d" rating. 4.5%
11/26 Form 4 Denali Therapeutics Inc. For: Nov 22 Filed by: Schuth Alexander O. 4.5%
TOP News Decliners
2/26
Denali Therapeutics Inc (NASDAQ: DNLI) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating.
-12.1%
3/30 Denali Therapeutics Inc (NASDAQ: DNLI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $21.00 price target on the stock. -11.1%
1/27 Denali Therapeutics Announces Proposed Offering of Common Stock -10.0%
1/15 Denali Therapeutics Inc (NASDAQ: DNLI) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -9.3%
9/25 Denali Therapeutics Inc (NASDAQ: DNLI) is now covered by analysts at Wedbush. They set a "neutral" rating on the stock. -9.1%
2/24 Denali Therapeutics Inc (NASDAQ: DNLI) is now covered by analysts at Jefferies Financial Group Inc. They set a "buy" rating and a $35.00 price target on the stock. -7.2%
5/10 Form 4/A Denali Therapeutics Inc. For: Apr 01 Filed by: Ho Carole -6.7%
1/29 Form 424B5 Denali Therapeutics Inc. -6.5%
3/12 Flagship Pioneering Announces the Launch of Repertoire Immune Medicines with Industry Veteran John G. Cox as Chief Executive Officer -6.2%
9/13 Denali Therapeutics Inc (NASDAQ: DNLI) is now covered by analysts at Nomura. They set a "buy" rating on the stock. -5.9%
3/30 Denali Therapeutics Inc (NASDAQ: DNLI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $21.00 price target on the stock. -11.1%
1/27 Denali Therapeutics Announces Proposed Offering of Common Stock -10.0%
1/15 Denali Therapeutics Inc (NASDAQ: DNLI) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -9.3%
9/25 Denali Therapeutics Inc (NASDAQ: DNLI) is now covered by analysts at Wedbush. They set a "neutral" rating on the stock. -9.1%
2/24 Denali Therapeutics Inc (NASDAQ: DNLI) is now covered by analysts at Jefferies Financial Group Inc. They set a "buy" rating and a $35.00 price target on the stock. -7.2%
5/10 Form 4/A Denali Therapeutics Inc. For: Apr 01 Filed by: Ho Carole -6.7%
1/29 Form 424B5 Denali Therapeutics Inc. -6.5%
3/12 Flagship Pioneering Announces the Launch of Repertoire Immune Medicines with Industry Veteran John G. Cox as Chief Executive Officer -6.2%
9/13 Denali Therapeutics Inc (NASDAQ: DNLI) is now covered by analysts at Nomura. They set a "buy" rating on the stock. -5.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: